Pdb63 - Cost-Effectiveness Analysis of Empagliflozin Treatment in Patients With Type 2 Diabetes and Chronic Heart Failure Based on Subgroup of Empa-Reg Outcome in the United Kingdom
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.768
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV